or Try an Advanced Search...

    Technical Analysis for SYRE - Spyre Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 37.38 -4.86% -1.91
    SYRE closed down 4.86 percent on Wednesday, May 15, 2024, on 72 percent of normal volume. It was able to find support at its 50 day moving average.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical SYRE trend table...
    Date Alert Name Type % Chg
    Bearish Engulfing Bearish 0.00%
    50 DMA Support Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Multiple of Ten Bearish Other 0.00%
    BB Squeeze + Upper Band Touch Range Contraction 0.00%
    Outside Day Range Expansion 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Crossed Above 50 DMA Bullish -4.86%
    Bollinger Band Squeeze Range Contraction -4.86%
    Stochastic Reached Overbought Strength -4.86%
    Older End-of-Day Signals for SYRE ...

       Recent Intraday Alerts

    Alert Time
    Fell Below 50 DMA about 22 hours ago
    50 DMA Support about 22 hours ago
    Outside Day about 22 hours ago
    Down 5% about 22 hours ago
    Fell Below Previous Day's Low about 22 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    SYRE Chart by TradingView
    Basic chart:

    Profile

    Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Immunology Antibodies Autoimmune Disease Monoclonal Antibody Antibody Inflammatory Bowel Disease

    Is SYRE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 15 Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
    May 9 Spyre Therapeutics GAAP EPS of -$1.20
    May 9 Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    Apr 19 Spyre Therapeutics files to sell 33.36M shares of common stock for holders
    Mar 18 Spyre Therapeutics climbs 5%, prices $180M private financing
    Feb 29 Spyre Therapeutics GAAP EPS of -$4.05
    Feb 29 Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    Feb 26 Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
    Feb 8 Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
    Feb 5 Spyre Therapeutics appoints Mark C. Mckenna to its Board
    See more SYRE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 47.97
    52 Week Low 2.66
    Average Volume 415,774
    200-Day Moving Average 21.82
    50-Day Moving Average 37.12
    20-Day Moving Average 34.86
    10-Day Moving Average 36.09
    Average True Range 3.00
    RSI (14) 54.95
    ADX 18.74
    +DI 27.72
    -DI 14.14
    Chandelier Exit (Long, 3 ATRs) 31.50
    Chandelier Exit (Short, 3 ATRs) 40.26
    Upper Bollinger Bands 38.52
    Lower Bollinger Band 31.20
    Percent B (%b) 0.84
    BandWidth 20.99
    MACD Line 0.47
    MACD Signal Line 0.01
    MACD Histogram 0.4615
    Fundamentals Value
    Market Cap 1.35 Billion
    Num Shares 36 Million
    EPS
    Price-to-Sales 939.83
    Price-to-Book 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 43.19
    Resistance 3 (R3) 43.58 42.03 42.22
    Resistance 2 (R2) 42.03 40.55 41.84 41.89
    Resistance 1 (R1) 39.71 39.64 38.94 39.32 41.57
    Pivot Point 38.16 38.16 37.78 37.97 38.16
    Support 1 (S1) 35.84 36.68 35.07 35.45 33.19
    Support 2 (S2) 34.29 35.77 34.10 32.87
    Support 3 (S3) 31.97 34.29 32.54
    Support 4 (S4) 31.58